• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Takeda Pharmaceutical Company Limited American Depositary Shares (each (NY: TAK )

    13.10 +0.09 (+0.69%)
    Official Closing Price Updated: 7:00 PM EST, Dec 20, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 1,848,722
    Open 13.04
    Bid (Size) 13.00 (2)
    Ask (Size) 13.60 (1)
    Prev. Close 13.01
    Today's Range 13.02 - 13.19
    52wk Range 12.57 - 15.08
    Shares Outstanding N/A
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Teva Pharmaceutical Releases Impressive Phase 2 Candidate Data For Gastro-Related Diseases
    Teva and Sanofi report positive Phase 2b data for duvakitug, showing significant remission in UC and CD patients, boosting analyst confidence and price targets. 
    Via Benzinga
    HUTCHMED to Receive Milestone Payment from Takeda following First European Reimbursement for FRUZAQLA® (fruquintinib)
    From HUTCHMED (China) Limited
    Via GlobeNewswire

    Performance

    YTD
    -8.65%
    -8.65%
    1 Month
    -2.09%
    -2.09%
    3 Month
    -12.02%
    -12.02%
    6 Month
    +1.71%
    +1.71%
    1 Year
    -6.83%
    -6.83%

    More News

    Read More
    Takeda Spotlights High-Value, Late-Stage Pipeline Accelerating the Development of Potential Transformative Treatments for Patients in Multiple Therapeutic Areas
    From Takeda Pharmaceutical Company Limited
    Via Business Wire
    Preview: Takeda Pharmaceutical's Earnings
    Via Benzinga
    Keros Therapeutics' Licensing Deal With Takeda Aligns With Broader Opportunity For Elritercept: Analyst
    Via Benzinga
    Takeda Strengthens Oncology Pipeline with Elritercept through Licensing Agreement with Keros Therapeutics
    From Takeda Pharmaceutical Company Limited
    Via Business Wire
    HUTCHMED Announces Launch by Takeda of FRUZAQLA® (fruquintinib) in Japan
    From HUTCHMED (China) Limited
    Via GlobeNewswire
    AC Immune's Active Immunotherapy Shows Antibody Responses In Early Parkinson's Patients
    Via Benzinga
    Urgency, Debate Mark COP29 As Leaders Push For Carbon Market Rules, Worry About Trump
    Via Benzinga
    Topics Climate Change
    Exposures Climate
    HUTCHMED to Receive First Commercial Milestone Payment Following Over US$200 Million in FRUZAQLA® (fruquintinib) Sales by Takeda
    From HUTCHMED (China) Limited
    Via GlobeNewswire
    Takeda Announces Strong First Half FY2024 Results and Raises Full Year Outlook
    From Takeda Pharmaceutical Company Limited
    Via Business Wire
    Takeda and Boston Medical Center Announce Innovative Collaboration to Help Tackle Decarbonization Across Health Care Ecosystem
    From Takeda Pharmaceutical Company Limited
    Via Business Wire
    Alumis' Investigational Lead Candidate Supports Superior Profile Than Bristol Myers' Commercialized Drug, Analyst Sees 170% Stock Upside
    Via Benzinga
    Johnson & Johnson Ends Phase 2 Study For Dengue Antiviral Amid R&D Reprioritization
    Via Benzinga
    Takeda Receives Approval for FRUZAQLA (fruquintinib) in Japan for the Treatment of Unresectable Advanced or Recurrent Colorectal Cancer
    From Takeda Pharmaceutical Company Limited
    Via Business Wire
    HUTCHMED Announces Japan Approval for FRUZAQLA® (fruquintinib) Received by Takeda
    From HUTCHMED (China) Limited
    Via GlobeNewswire
    Analysts Predict 85% Upside for Wave Life Sciences After Rate Cut
    Via MarketBeat
    Topics Economy
    Exposures Interest Rates
    Takeda to Present Additional Clinical Trial Study Data Highlighting the Impact of Orexin Agonist TAK-861 on the Burden of Narcolepsy at Sleep Europe 2024
    From Takeda Pharmaceutical Company Limited
    Via Business Wire
    Takeda Commits Over $32 Million in Five New Global Corporate Social Responsibility Partnerships to Further Drive Health Impact in 93 Countries
    From Takeda Pharmaceutical Company Limited
    Via Business Wire
    Protagonist Therapeutics' Two Investigational Candidates Target Over $10B Market, Bullish Analyst Opines
    Via Benzinga
    Enliven Therapeutics' Leukemia Candidate Could Challenge Pfizer, AstraZeneca In Broader Target Market: Analyst
    Via Benzinga
    Shortage Relief: More Takeda's Vyvanse For ADHD On the Way As US Ramps Up Production
    Via Benzinga
    Ascendis' Hypoparathyroidism Drug Scores FDA Approval As First and Only Treatment, Replacing Takeda's Drug Discontinued Due To Supply Issues
    Via Benzinga
    Exposures Product Safety
    New Study Reveals How Classical Music Could Revolutionize Depression Care
    Via PressReach
    Exposures Product Safety
    Why Is Japanese Drugmaker Takeda Pharmaceutical Stock Trading Higher On Wednesday?
    Via Benzinga
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.